Clearstead Advisors’s Galectin Therapeutics GALT Stock Holding History

Clearstead Advisors’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$27.8K	Hold	6,000	–	–	﹤0.01%	1693
2026 Q1	$16.7K	Hold	6,000	–	–	﹤0.01%	1485
2025 Q4	$25K	Hold	6,000	–	–	﹤0.01%	1648
2025 Q3	$25.4K	Hold	6,000	–	–	﹤0.01%	1536
2025 Q2	$12.7K	Hold	6,000	–	–	﹤0.01%	1804
2025 Q1	$7.32K	Hold	6,000	–	–	﹤0.01%	1686
2024 Q4	$7.74K	Buy	6,000 +3,000	+100%	+$7.19K	﹤0.01%	1639
2024 Q3	$8.25K	Hold	3,000	–	–	﹤0.01%	1619
2024 Q2	$6.78K	Hold	3,000	–	–	﹤0.01%	1627
2024 Q1	$9.24K	Hold	3,000	–	–	﹤0.01%	1065
2023 Q4	$4.98K	Sell	3,000 -3,000	-50%	-$5.82K	﹤0.01%	1163
2023 Q3	$11.5K	Buy	6,000 +4,500	+300%	+$7.4K	﹤0.01%	1100
2023 Q2	$2.16K	Buy	+1,500	New	+$2.54K	﹤0.01%	1132

Other funds holding GALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Clearstead Advisors's GALT Position: Q2 2026 in Review

Clearstead Advisors held its Galectin Therapeutics (GALT) position steady in Q2 2026 at 6,000 shares worth $27.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1693.

Clearstead Advisors first reported a position in GALT in Q2 2023 and has held it in 13 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

Clearstead Advisors held 6,000 shares of Galectin Therapeutics worth $27.8K as of Q2 2026.
Clearstead Advisors left its Galectin Therapeutics share count unchanged in Q2 2026.
Galectin Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #1693 holding.
Clearstead Advisors first reported a position in Galectin Therapeutics in Q2 2023 and has held it in 13 quarters since.
98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.